Dr. Hodjat Rabbani
A Visionary Leader in Cancer Immunotherapy
Dr. Rabbani is a distinguished researcher and thought leader in cancer immunotherapy, focusing on novel antibody development and non-invasive diagnostic techniques. With a career spanning over 30 years, his work bridges research innovation and clinical application, improving outcomes for cancer patients worldwide.
Achievements & Recognitions
Year: [Award/Recognition Title]
Recipient of the [Award Name] for advancements in cancer research (Year).
Published in leading journals like [Name], contributing over [X] peer-reviewed articles.
Cancer-Specific Innovations:
“Dr. Rabbani’s work on antibodies like ROR1 has redefined chronic lymphocytic leukemia diagnostics.”
Career Highlights
Dr. Hodjattallah Rabbani, Ph.D., Associate Professor of Experimental Oncology, is the visionary founder of Padza and a pioneer in cancer immunotherapy, innovative research, targeted diagnostic solutions. and antibody production. His academic journey and contributions have shaped Padza’s commitment to innovation and excellence.
Publications & Contributions
Patents
Key Patents
- ROR1-linked 67GA monoclonal antibody for imaging breast cancer.
- Antibody against Fibromodulin for cancer diagnosis and therapy.
- Monoclonal antibody targeting Sortilin for bladder carcinoma diagnostics.
Publications
- Publications: (Include key papers demonstrating practical applications of Padza’s antibodies (e.g., cell surface markers for diagnostics). Avoid overloading with technical data; instead, link to a downloadable PDF for interested parties.)
- Use expandable lists to highlight five key papers with citations:
- “Fibromodulin: A Novel Marker for Cancer Relapse in Breast Tumors” (2017).
- Include DOI links for credibility.
Publication Title: “Development of HRP-Conjugated Antibodies for Diagnostic Use.”
Year: 20XX
Journal/Source: Published in [Journal Name].
Expertise/Research Focus
Dr. Rabbani is at the forefront of cancer immunotherapy, blending expertise in antibody development with innovative diagnostic strategies to tackle complex challenges in oncology. His groundbreaking contributions have transformed research outcomes and paved the way for novel treatments.
- Over three decades leading antibody engineering research at Avicenna Research Institute and Karolinska Institute.
- Established Padza in 2016 to localize antibody production, bridging academic insights with practical biotechnology applications.
- Authored/co-authored over 200 scientific publications focused on cancer immunotherapy.
- Instrumental in developing antibodies for critical cancer markers like ROR1, Fibromodulin, and Sortilin.
- Developed diagnostic tools and therapies targeting chronic lymphocytic leukemia, breast cancer, and bladder carcinoma.
- Dr. Rabbani’s leadership has been central to advancing Padza’s vision, ensuring groundbreaking contributions to cancer research and therapy.
Science is about innovation that touches lives—this is our guiding principle at Padza.
Contact Dr. Hodjat Rabbani
Collaborate with Dr. Rabbani to advance research and improve cancer treatment outcomes.